158 completed, 18 terminated, 14 unknown, 10 withdrawn. 201 Phase 3, 19 Phase 2.
By phase and status
Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic
Trials (filtered) newest first · largest first
All 201 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | 880 | 2025-06-02 | 2026-06-29 |
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | 50 | 2019-09-01 | 2019-09-12 |
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | 440 | 2019-03-29 | 2019-08-28 |
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 Elbasvir, Grazoprevir 50-100Mg Oral Tablet - Hepatitis C, Chronic | Phase 3 | Completed | 30 | 2018-07-01 | 2020-11-20 |
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 100 | 2018-06-06 | 2020-03-17 |
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | 150 | 2018-02-02 | 2021-05-18 |
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | 100 | 2017-12-01 | 2018-09-20 |
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection Placebo, Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 546 | 2017-10-04 | 2019-12-23 |
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial Administration of DAA-based treatment - Hepatocellular Carcinoma, Hepatitis C, Chronic | Phase 3 | Unknown | 80 | 2017-10-01 | 2018-06-11 |
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 160 | 2017-09-29 | 2019-11-21 |
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic | Phase 3 | Completed | 380 | 2017-08-21 | 2019-12-11 |
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 230 | 2017-08-07 | 2019-09-04 |
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis Zepatier Oral Product - Hepatitis C, Chronic | Phase 3 | Completed | 82 | 2017-06-12 | 2019-01-09 |
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C KW-136 capsule, Sofosbuvir - Hepatitis C, Chronic | Phase 3 | Completed | 371 | 2017-06-07 | 2019-06-25 |
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 343 | 2017-04-28 | 2020-07-13 |
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment Glecaprevir/pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | 101 | 2017-03-28 | 2019-03-04 |
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV) | Phase 2 / Phase 3 | Completed | 129 | 2017-03-20 | 2023-05-09 |
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection | Phase 3 | Completed | 33 | 2016-11-21 | 2022-05-04 |
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Ombitasvir/paritaprevir/ritonavir - Chronic Hepatitis C Virus | Phase 3 | Withdrawn | | 2016-09-01 | 2016-12-05 |
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C | Phase 3 | Completed | 141 | 2016-06-01 | 2021-03-23 |
Showing 20 of 201. Sign in to see all of them.
Narrower conditions
Hepatitis C (93) · Fibrosis (18) · Hepatitis (11) · Liver Cirrhosis (10) · Liver Diseases (8) · Acquired Immunodeficiency Syndrome (6) · Infections (6) · Virus Diseases (6) · Hepatitis, Chronic (5) · Carcinoma, Hepatocellular (4) · Digestive System Diseases (4) · Enterovirus Infections (4) · Flaviviridae Infections (4) · Hepatitis, Viral, Human (4)
Broader conditions
Blood-Borne Infections (201) · Chronic Disease (201) · Communicable Diseases (201) · Disease Attributes (201) · Pathologic Processes (201) · Pathological Conditions, Signs and Symptoms (201) · Digestive System Diseases (197) · Flaviviridae Infections (197) · Hepatitis, Viral, Human (197) · RNA Virus Infections (197) · Hepatitis, Chronic (196) · Infections (195) · Virus Diseases (195) · Liver Diseases (193) · Hepatitis (190)
Interventions
Ribavirin (122) · peginterferon alfa-2a (51) · peginterferon alfa-2b (39) · ombitasvir (25) · paritaprevir (22) · dasabuvir (21) · glecaprevir and pibrentasvir (21) · Sofosbuvir (17) · glecaprevir (17) · pibrentasvir (16) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (14) · Viekira Pak (12) · telaprevir (11) · Simeprevir (8) · ledipasvir, sofosbuvir drug combination (8)
Sponsors
AbbVie (39) · Merck Sharp & Dohme LLC (33) · Gilead Sciences (11) · Hoffmann-La Roche (7) · Tanabe Pharma Corporation (7) · Boehringer Ingelheim (6) · French National Agency for Research on AIDS and Viral Hepatitis (6) · AbbVie (prior sponsor, Abbott) (5) · Bausch Health Americas, Inc. (4) · Janssen Pharmaceutical K.K. (4) · Janssen-Cilag International NV (4) · ANRS, Emerging Infectious Diseases (3) · Debiopharm International SA (3) · Foundation for Liver Research (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)
Countries
France (40) · United States (40) · Canada (32) · Germany (32) · Spain (32) · United Kingdom (27) · Puerto Rico (24) · Australia (22) · Italy (21) · Belgium (19) · Poland (19) · Egypt (17) · Japan (14) · Russia (14) · Taiwan (13)
Top investigators
Ralph T. Doyle (4) · Eric Cohen, MD (3) · Eric Bellissant, MD, PhD (2) · Fumitaka Suzuki, MD (2) · Gao Zhiliang, Doctor (2)
Results publications
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 29377566, PMID 30868245, PMID 25040192, PMID 26947564, PMID 27553375, PMID 28193518, PMID 29404492, PMID 29461687, PMID 35174470, PMID 20189674, PMID 22626609, PMID 23607593, PMID 24126097, PMID 25196718, PMID 25583164, PMID 25777337, PMID 26173631, PMID 26321288, PMID 26936417, PMID 27920566, PMID 29180522, PMID 29909549, PMID 32682494, PMID 17311621, PMID 17573387, PMID 17894303, PMID 17894323, PMID 18167062, PMID 18237873, PMID 18848939, PMID 19052125, PMID 19291787, PMID 19445938, PMID 19625712, PMID 19676128, PMID 19747918, PMID 19766643, PMID 19852963, PMID 20070284, PMID 20211180, PMID 20362695, PMID 20512062, PMID 20564351, PMID 20600013, PMID 20600017
NIH funding
2014 (12), 2015 (11), 2016 (5), 2004 (3), 2005 (3), 2008 (2), 2009 (2), R01DA026727 (1), U01DK067767 (1)